Can a simple questionnaire help lung cancer patients make better decisions?
NCT ID NCT06743308
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new screening tool can help people with advanced lung cancer better understand their illness and treatment goals. About 100 patients will either use the tool or receive usual care. The goal is to see if the tool leads to more informed decisions that match what patients truly want.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Screening tool (questionnaire)
- What this could lead to
- If it works, this could help doctors better understand what patients know and want, leading to care that matches patients' values.
- What could go wrong
- This is a small, early study testing a questionnaire, not a treatment. It may not change patient understanding or outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Within 3 months of biopsy-confirmed diagnosis of stage IV lung cancer * Age 18 or over * English speaking * Attending a follow-up visit at the thoracic medical oncology clinic * Plans to receive or actively undergoing cancer-directed systemic treatment at MD Anderson Exclusion Criteria: • Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new tracers make many cancers light up on scans?
- Can tumor avatars reveal why cancer hits minorities harder?
- Can we predict and treat cancer wasting better? a new study investigates
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- New PET tracer could spot cancers that standard scans overlook